| RPP # | Description | Requiring Office | Submission Due Date | |
|---|---|---|---|---|
| Upcoming Opportunity | Prize Administration for Innovation in Clinical Manufacturing | BARDA anticipates requesting project proposals for a partner(s) that has the expertise to design, promote, and administer effective prize competitions. With this prize approach, BARDA aims to spur participation from a broad range of organizations, including nontraditional private partners, to develop technical solutions that thrive beyond prize award. The objective of the prize competitions would be to catalyze innovation in new manufacturing technologies that will improve access and enable faster, lower cost, rapid, and flexible production of medical countermeasures for health security threats. BARDA anticipates to support at least two prizes through the Prize Administrator selected through this Request for Project Proposals (RPP). The topics for those prizes are anticipated to be: (1) advance clinical testing of vaccines that leverage new GMP manufacturing approaches for single dose vaccines and (2) innovative approaches to improve the speed, yield, and scale up of non-vector/non nucleic acid-based vaccine manufacturing platforms (i.e., not RNA/DNA or viral-based) to enable rapid sequence-to-release of GMP clinical trial material in line with 100-day mission goals and Phase 1 testing. | Tentative Release Q2-Q3FY25 | |
| RPP 24-07 - CentralIEIDLab | Central Influenza and Emerging Infectious Diseases Vaccine Immunoassay Laboratory Services | BARDA is seeking to partner with laboratories with existing capabilities to function as a central immunoassay laboratory and perform quality-assured immunoassays to support advanced research and development of influenza and emerging infectious disease vaccines using samples collected from nonclinical studies and clinical trials. Additionally, the central immunoassay laboratory will provide rapid response capability to qualify/validate immune assays for newly emerged viral strains or variants and test clinical and/or nonclinical samples in an accelerated fashion in the event of an influenza virus outbreak. Data from these assays may be used in primary, secondary, and exploratory endpoint analyses for vaccine clinical trials, cross-reactivity testing for pandemic readiness and response purposes or perform correlates of protection analyses. | 5/30/2025 |
| RPP # (Date) | Requirement Topic | Closed Date |
|---|---|---|
| RPP-24-08-mRNALongTerm (08/30/2024) | Rapid Pandemic Influenza and Emerging Infectious Disease Vaccine Development and Response Capability | 2/28/2025 |
| RPP-24-02-OralVx (09/09/2024) | NextGen Oral Formulation Vaccines for COVID-19 | 11/15/2024 |
| RPP-24-02-ODM (08/13/2024) | On-Demand Manufacturing | 9/25/2024 |
| RPP-24-03-SmMol (08/05/2024) | COVID-19 Small Molecule Therapeutics for PrEP | 9/20/2024 |
| RPP-24-06-DxR2 (3/27/2024) | Biothreat Diagnostic Rapid Response | 5/17/2024 |
| RPP-24-03-Treatment (02/21/2024) | Project NextGen: Therapeutics | 5/13/2024 |
| RPP-24-05-NGClinMfg (01/16/2024) | Project NextGen: Innovation in Clinical Manufacturing of COVID-19 Vaccines | 04/19/2024 |
| RPP-24-04-NGVxStats (2/23/2024) | NextGen Vaccines: Statistical Support, Correlates of Protection, and Meta-analysis | 03/27/2024 |
| RPP-24-04-NGVxAssays (2/15/2024) | NextGen Vaccines: Immune Assays | 3/22/2024 |
| RPP-24-02-Retail (2/2/2024) | Enabling Technology – Decentralized Clinical Trial – Retail/Pharmacy Focus | 03/20/2024 |
| RPP-24-02-HomeFocus (11/30/2023) | Enabling Technology – Decentralized Clinical Trial – Home Focus | 01/19/2024 |
| RPP-24-03-PrEP (11/30/2023) | COVID-19 Monoclonal Antibody Therapeutics for PrEP | 01/19/2024 |
| RPP-24-04-NGVx (11/30/2023) | NextGen Vaccinations: Phase 2B Clinical Trial Execution | 01/10/2024 |
RPP-24-01-mRNA | Accelerating Near-Term Availability of mRNA-based Pandemic Influenza Vaccine | 12/4/2023 |
